利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.022 秒)

    Therapeutic Uses For Aminosterol Compounds
    1.
    发明申请
    Therapeutic Uses For Aminosterol Compounds 审中-公开
    氨基甾醇化合物的治疗用途

    公开(公告)号：US20080221075A1

    公开(公告)日：2008-09-11

    申请号：US12041440

    申请日：2008-03-03

    申请人： Michael Zasloff ,  Jon Williams ,  William Kinney ,  Mark Anderson ,  Michael McLane

    发明人： Michael Zasloff ,  Jon Williams ,  William Kinney ,  Mark Anderson ,  Michael McLane

    IPC分类号： A61K31/56 ,  C07J41/00 ,  A61P3/04

    CPC分类号： A61K31/575 ,  C07J41/0055

    摘要： A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG. 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. Various pharmaceutical products may be produced including this pharmaceutical composition. Such pharmaceutical products may be used for the treatment of obesity or diabetes. Methods for using the pharmaceutical compositions also are described. In these methods, various diseases are treated or other body functions are activated or inhibited by administering an effective amount of the pharmaceutical composition. For example, diabetes and obesity may be treated by administering an effective amount of the pharmaceutical compositions. Weight gain, and growth factor production can be inhibited by administering an effective amount of these pharmaceutical compositions. Appetite can be suppressed by administering an effective amount of the pharmaceutical compositions, and a diuretic effect can be produced.

    摘要翻译： 药物组合物包含作为活性成分的如图14所示的根据式1436的化合物。 1，或其药学上可接受的盐，和药学上可接受的载体或赋形剂。 可以生产包括该药物组合物的各种药物。 这样的药物可以用于治疗肥胖或糖尿病。 还描述了使用药物组合物的方法。 在这些方法中，通过施用有效量的药物组合物来治疗各种疾病或其他身体功能被激活或抑制。 例如，可以通过施用有效量的药物组合物来治疗糖尿病和肥胖症。 通过施用有效量的这些药物组合物可以抑制体重增加和生长因子产生。 可以通过施用有效量的药物组合物来抑制食欲，并且可以产生利尿作用。

    Therapeutic Uses for an Aminosterol Compound
    2.
    发明申请
    Therapeutic Uses for an Aminosterol Compound 有权
    氨基甾醇化合物的治疗用途

    公开(公告)号：US20130281419A1

    公开(公告)日：2013-10-24

    申请号：US13673500

    申请日：2012-11-09

    申请人： Michael Zasloff ,  Jon Williams ,  William Kinney ,  Mark Anderson ,  Michael McLane

    发明人： Michael Zasloff ,  Jon Williams ,  William Kinney ,  Mark Anderson ,  Michael McLane

    IPC分类号： A61K31/575

    CPC分类号： A61K31/575 ,  C07J41/0055

    摘要： A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG. 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. Various pharmaceutical products may be produced including this pharmaceutical composition. Such pharmaceutical products may be used for the treatment of obesity or diabetes. Methods for using the pharmaceutical compositions also are described. In these methods, various diseases are treated or other body functions are activated or inhibited by administering an effective amount of the pharmaceutical composition. For example, diabetes and obesity may be treated by administering an effective amount of the pharmaceutical compositions. Weight gain and growth factor production can be inhibited by administering an effective amount of these pharmaceutical compositions. Appetite can be suppressed by administering an effective amount of the pharmaceutical compositions, and a diuretic effect can be produced.

    摘要翻译： 药物组合物包含作为活性成分的如图14所示的根据式1436的化合物。 1，或其药学上可接受的盐，和药学上可接受的载体或赋形剂。 可以生产包括该药物组合物的各种药物。 这样的药物可以用于治疗肥胖或糖尿病。 还描述了使用药物组合物的方法。 在这些方法中，通过施用有效量的药物组合物来治疗各种疾病或其他身体功能被激活或抑制。 例如，可以通过施用有效量的药物组合物来治疗糖尿病和肥胖症。 通过施用有效量的这些药物组合物可以抑制体重增加和生长因子产生。 可以通过施用有效量的药物组合物来抑制食欲，并且可以产生利尿作用。

    Therapeutic uses for aminosterol compounds
    3.
    发明授权
    Therapeutic uses for aminosterol compounds 有权
    氨基甾醇化合物的治疗用途

    公开(公告)号：US07410959B1

    公开(公告)日：2008-08-12

    申请号：US09885247

    申请日：2000-07-13

    申请人： Michael Zasloff ,  Jon Williams ,  William Kinney ,  Mark Anderson ,  Michael McLane

    发明人： Michael Zasloff ,  Jon Williams ,  William Kinney ,  Mark Anderson ,  Michael McLane

    IPC分类号： A61K31/56 ,  A61K31/555 ,  A01N55/02 ,  C07J41/00

    CPC分类号： A61K31/575 ,  C07J41/0055

    摘要： A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG. 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. Various pharmaceutical products may be produced including this pharmaceutical composition. Such pharmaceutical products may be used for the treatment of obesity or diabetes. Methods for using the pharmaceutical compositions also are described. In these methods, various diseases are treated or other body functions are activated or inhibited by administering an effective amount of the pharmaceutical composition. For example, diabetes and obesity may be treated by administering an effective amount of the pharmaceutical compositions. Weight gain, and growth factor production can be inhibited by administering an effective amount of these pharmaceutical compositions. Appetite can be suppressed by administering an effective amount of the pharmaceutical compositions, and a diuretic effect can be produced.

    摘要翻译： 药物组合物包含作为活性成分的如图14所示的根据式1436的化合物。 1，或其药学上可接受的盐，和药学上可接受的载体或赋形剂。 可以生产包括该药物组合物的各种药物。 这样的药物可以用于治疗肥胖或糖尿病。 还描述了使用药物组合物的方法。 在这些方法中，通过施用有效量的药物组合物来治疗各种疾病或其他身体功能被激活或抑制。 例如，可以通过施用有效量的药物组合物来治疗糖尿病和肥胖症。 通过施用有效量的这些药物组合物可以抑制体重增加和生长因子产生。 可以通过施用有效量的药物组合物来抑制食欲，并且可以产生利尿作用。

    Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
    4.
    发明授权
    Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities 有权
    使用角质胺与其他抗癌剂或方式联合治疗癌症

    公开(公告)号：US06596712B2

    公开(公告)日：2003-07-22

    申请号：US09803740

    申请日：2001-03-12

    申请人： Michael Zasloff ,  Jon Williams ,  Mitchell H. Sokoloff

    发明人： Michael Zasloff ,  Jon Williams ,  Mitchell H. Sokoloff

    IPC分类号： A61K3156

    CPC分类号： A61K31/575 ,  A61K31/00 ,  A61K33/24 ,  A61K2300/00

    摘要： A method for treating a tumor includes a first treatment procedure using a conventional cancer treatment technique, and a second treatment procedure which includes administering an effective amount of squalamine. Synergistically effective amounts are preferred. The first treatment procedure may be a treatment with one or more conventional cytotoxic chemical compounds. As examples, the cytotoxic chemical compound may be a nitrosourea (such as BCNU), cyclophosphamide, doxorubicin, 5-fluorouracil, paclitaxel and its derivatives, cisplatin or other platinum containing cancer treating agents. Alternatively, the first treatment may be a treatment with one or more conventional anti-hormonal agents. As examples, the anti-hormonal agents may be a LHRH (luteinizing hormone releasing hormone) agonist or an anti-androgen such as flutamide, biclutamide, nilutamide, and luprolide. These conventional cancer treatments compounds and the squalamine may be administered by any suitable route. The first treatment procedure may take place prior to the second treatment procedure, after the second treatment procedure, or the two treatment procedures may take place simultaneously. As an alternative, the first treatment procedure may be a conventional radiation treatment regimen. As a further alternative the first treatment procedure may be a combination of treatment with one or more conventional cytotoxic chemical compounds and a conventional radiation treatment regimen.

    摘要翻译： 治疗肿瘤的方法包括使用常规癌症治疗技术的第一治疗方法和包括给予有效量的角鲨胺的第二治疗方法。 协同有效量是优选的。 第一种治疗方法可以是用一种或多种常规细胞毒性化学化合物治疗。 作为实例，细胞毒性化合物可以是亚硝基脲（例如BCNU），环磷酰胺，多柔比星，5-氟尿嘧啶，紫杉醇及其衍生物，顺铂或其它含铂的癌症治疗剂。 或者，第一种治疗可以是用一种或多种常规抗激素剂治疗。 作为实例，抗激素剂可以是LHRH（黄体生成激素释放激素）激动剂或抗雄激素，例如氟他胺，双氯吡格胺，尼鲁替丁和氟洛西林。 这些常规的癌症治疗化合物和角鲨胺可以通过任何合适的途径施用。 第一处理程序可以在第二处理程序之前，第二处理程序之后进行，或者两个处理程序可以同时进行。 作为替代方案，第一种治疗方法可以是常规的放射治疗方案。 作为另一种替代方案，第一种治疗方法可以是与一种或多种常规细胞毒性化学化合物的治疗和常规放射治疗方案的组合。

    Treatment of carcinomas using squalamine in combination with other anti-cancer agents
    5.
    发明授权
    Treatment of carcinomas using squalamine in combination with other anti-cancer agents 失效
    使用角鲨胺与其他抗癌剂联合治疗癌症

    公开(公告)号：US6147060A

    公开(公告)日：2000-11-14

    申请号：US840706

    申请日：1997-04-25

    申请人： Michael Zasloff ,  Jon Williams

    发明人： Michael Zasloff ,  Jon Williams

    IPC分类号： A61K45/00 ,  A61K31/00 ,  A61K31/40 ,  A61K31/407 ,  A61K31/475 ,  A61K31/505 ,  A61K31/513 ,  A61K31/575 ,  A61K31/675 ,  A61K31/70 ,  A61K31/7028 ,  A61K31/7034 ,  A61K31/704 ,  A61K31/7042 ,  A61K31/7048 ,  A61K31/7052 ,  A61K31/706 ,  A61K31/7064 ,  A61K33/24 ,  A61P35/00 ,  A61K31/66 ,  A61K31/175 ,  A61K31/56

    CPC分类号： A61K31/575 ,  A61K33/24

    摘要： A method for treating a tumor includes a first treatment procedure using a conventional cancer treatment technique, and a second treatment procedure which includes administering an effective amount of squalamine. The first treatment procedure may be a treatment with one or more conventional cytotoxic chemical compounds. As examples, the cytotoxic chemical compound may be a nitrosourea (such as BCNU), cyclophosphamide, adriamycin, 5-fluorouracil, paclitaxel and its derivatives, cisplatin or other platinum containing cancer treating agents. The cytotoxic chemical compound and the squalamine may be administered by any suitable route. The first treatment procedure may take place prior to the second treatment procedure, after the second treatment procedure, or the two treatment procedures may take place simultaneously. In one example, the first treatment procedure (e.g., a one time intravenous dosage of BCNU) is completed before the second treatment procedure with squalamine begins. As an alternative, the first treatment procedure may be a conventional radiation treatment regimen.

    摘要翻译： 治疗肿瘤的方法包括使用常规癌症治疗技术的第一治疗方法和包括给予有效量的角鲨胺的第二治疗方法。 第一种治疗方法可以是用一种或多种常规细胞毒性化学化合物治疗。 作为实例，细胞毒性化合物可以是亚硝基脲（如BCNU），环磷酰胺，阿霉素，5-氟尿嘧啶，紫杉醇及其衍生物，顺铂或其他含铂的癌症治疗剂。 细胞毒性化合物和角鲨胺可以通过任何合适的途径施用。 第一处理程序可以在第二处理程序之前，第二处理程序之后进行，或者两个处理程序可以同时进行。 在一个实例中，首先处理程序（例如，一次性静脉注射剂量的BCNU）在开始第二次治疗过程之前完成。 作为替代方案，第一种治疗方法可以是常规的放射治疗方案。

    Interactive animation
    8.
    发明授权
    Interactive animation 有权
    互动动画

    公开(公告)号：US07843455B2

    公开(公告)日：2010-11-30

    申请号：US11746293

    申请日：2007-05-09

    申请人： Nicholas Bridger ,  Ed Bainbridge ,  Jon Williams ,  Matthew Humphries ,  David Navvarro ,  Andy Brown ,  David Pridmore ,  Jon Maine

    发明人： Nicholas Bridger ,  Ed Bainbridge ,  Jon Williams ,  Matthew Humphries ,  David Navvarro ,  Andy Brown ,  David Pridmore ,  Jon Maine

    IPC分类号： G06T13/00

    CPC分类号： A63F13/42 ,  A63F13/10 ,  A63F13/57 ,  A63F13/833 ,  A63F2300/6045 ,  A63F2300/64 ,  A63F2300/8029 ,  G06T13/00 ,  G06T2213/12

    摘要： An interactive animation environment. The interactive animation environment includes at least one user-controlled object, and the animation method for providing this environment includes determining a position of the user-controlled object, defining a plurality of regions about the position, detecting a user input to move the position of the user-controlled object, associating the detected user input to move the position of the user-controlled object with a region in the direction of movement, and providing an animation of the user-controlled object associated with the mapped region. A system and controller for implementing the method is also disclosed. A computer program and computer program product for implementing the invention is further disclosed.

    摘要翻译： 交互式动画环境。 交互式动画环境包括至少一个用户控制对象，并且用于提供该环境的动画方法包括确定用户控制对象的位置，定义关于该位置的多个区域，检测用户输入以移动 所述用户控制对象将所检测到的用户输入相关联，以使所述用户控制对象的位置与所述移动方向上的区域相关联，以及提供与所述映射区域相关联的所述用户控制对象的动画。 还公开了一种用于实现该方法的系统和控制器。 进一步公开了用于实现本发明的计算机程序和计算机程序产品。

    Distributed Physics Based Training System and Methods
    10.
    发明申请
    Distributed Physics Based Training System and Methods 有权
    基于分布式物理的训练系统和方法

    公开(公告)号：US20090099824A1

    公开(公告)日：2009-04-16

    申请号：US12085541

    申请日：2006-11-28

    申请人： Mark Falash ,  Eytan Pollak ,  Yushan Chen ,  Jon Williams

    发明人： Mark Falash ,  Eytan Pollak ,  Yushan Chen ,  Jon Williams

    IPC分类号： G06G7/70

    CPC分类号： G09B9/00 ,  H04L67/38

    摘要： A distributed simulation system is composed of simulator stations linked over a network that each renders real-time video imagery for its user from scene data stored in its data storage. The simulation stations are each connected with a physics farm that manages the virtual objects in the shared virtual environment based on their physical attribute data using physics engines, including an engine at each simulation station. The physics engines of the physics farm are assigned virtual objects so as to reduce the effects of latency, to ensure fair fight requirements of the system, and, where the simulation is of a vehicle, to accurately model the ownship of the user at the station. A synchronizer system is also provided that allows for action of simulated entities relying on localized closed loop controls to cause the entities to meet specific goal points at specified system time points.

    摘要翻译： 分布式仿真系统由通过网络链接的模拟器站组成，每个模拟站通过存储在其数据存储器中的场景数据为其用户呈现实时视频图像。 模拟站各自与物理场连接，物理场基于使用物理引擎（包括每个模拟站的引擎）的物理属性数据来管理共享虚拟环境中的虚拟对象。 物理场的物理引擎被分配虚拟对象，以减少延迟的影响，以确保系统的公平对抗要求，并且在模拟车辆的情况下，准确地对车站用户进行建模 。 还提供了同步器系统，其允许依赖于本地化闭环控制的模拟实体的动作使得实体在指定的系统时间点满足特定的目标点。